

Results of 2019 Annual Meeting of Stockholders

9 May 2019 - Minnesota, United States and Melbourne, Australia – Osprey Medical (ASX:OSP) held its Annual Meeting of Stockholders today and, in accordance with ASX Listing Rule 3.13.2, is pleased to announce that each of the resolutions put to stockholders as set forth in the Notice of Annual Meeting and Proxy Statement dated 10 April 2019 were passed.

The information required under Section 251AA of the Corporations Act is attached.

Brendan Case
Australian Secretary

Contact details:

Media

Kyahn Williamson
Buchan Consulting
M: (61) 401 018 828
kwilliamson@we-buchan.com

Investors

Thomas Duthy
Nemean Group
M: (61) 402 493 727
tduthy@ospreymed.com

Company

Doug Schoenberg
VP of Marketing
T: (952) 955 8230
dschoenberg@ospreymed.com

About Osprey Medical (ASX: OSP)

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast-Induced Acute Kidney Injury (CI-AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

Foreign Ownership Restriction

Osprey's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Res No	Resolution	Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)			Resolution Result
		Votes For	Votes Against	Votes Discretionary	Votes Abstain	For	Against	Abstain	Carried/ Not Carried
1A	Election of Mrs Sandra Lesenfants as a Class III Director	130,489,247	0	20,000	161,639	130,509,247 99.88%	0	161,639 0.12%	Carried
1B	Election of Mr Michael McCormick as a Class III Director	130,491,670	0	20,000	158,039	130,511,670 99.88%	0	158,039 0.12%	Carried
2	Ratification and approval of prior issue of CHES Depository Interests	104,309,556	87,132	38,425	160,539	104,347,981 99.76%	87,132 0.08%	160,539 0.16%	Carried
3	Approval of 10% Placement Facility	130,349,110	254,180	38,425	85,971	130,387,535 99.74%	254,180 0.19%	85,971 0.07%	Carried
4	Approval of Stock Option Exchange Offer	122,531,815	8,123,649	38,435	23,297	122,570,250 93.77%	8,123,649 6.21%	23,297 0.02%	Carried
5	Approval of amendment to 2016 Stock Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder	122,521,859	8,086,105	38,425	73,297	122,560,284 93.76%	8,086,105 6.18%	73,297 0.06%	Carried
6	Approval of amendment to the Amended and Restated Certificate of Incorporation to increase the authorized shares of common stock	130,080,860	535,104	38,425	73,297	130,119,285 99.53%	535,104 0.41%	73,297 0.06%	Carried
7	Grant of Stock Option Exchange Offer Options to Mr John Erb, Chairman of the Company	114,145,284	16,520,180	38,425	15,797	114,183,709 87.35%	16,520,180 12.64	15,797 0.01%	Carried
8	Grant of Stock Option Exchange Offer Options to Mr Neville Mitchell, a Director of the Company	114,145,284	16,520,180	38,425	15,797	114,183,709 87.35%	16,520,180 12.64	15,797 0.01%	Carried
9	Grant of Stock Option Exchange Offer Options to Mr Michael McCormick, President & CEO and a Director of the Company	122,519,431	8,096,033	38,425	65,797	122,557,856 93.76%	8,096,033 6.19	65,797 0.05%	Carried

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Res No	Resolution	Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)			Resolution Result
		Votes For	Votes Against	Votes Discretionary	Votes Abstain	For	Against	Abstain	Carried/ Not Carried
10	Grant of 2019 Options to Mr John Erb, Chairman of the Company	120,593,492	10,017,347	38,425	70,422	120,631,917 92.28%	10,017,347 7.67	70,422 0.05%	Carried
11	Grant of 2019 Options to Mrs Sandra Lesenfants, a Director of the Company	120,589,892	10,017,347	38,425	74,022	120,628,317 92.28%	10,017,347 7.67	74,022 0.06%	Carried
12	Grant of 2019 Options to Mr Neville Mitchell, a Director of the Company	120,593,492	10,017,347	38,425	70,422	120,631,917 92.28%	10,017,347 7.67	70,422 0.05%	Carried
13	Grant of 2019 Options to Mr Michael McCormick, President & CEO and a Director of the Company	122,501,609	8,109,230	38,425	70,422	122,540,034 93.74%	8,109,230 6.21	70,422 0.05%	Carried